◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › A › ADMA

ADMA Biologics Inc (ADMA) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-06

ADMA Biologics Inc (ADMA) operates in the BIOTECHNOLOGY industry and is headquartered in Ramsey, United States with about 640 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, ADMA reported $510M in revenue and $147M in net income.

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.

Interactive charts & full statements → Open the ADMA valuation workbench →

ADMA Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$511M	$510M	$426M	$258M	$154M	$81M	$42M	$29M	$17M	$23M	$11M	$7M	$6M	$3M	$1M	—	—	—	—	—	—
Gross Profit	$332M	$293M	$220M	$89M	$35M	$1M	($19M)	($10M)	($25M)	($6M)	$4M	$3M	$2M	$1M	$0M	—	—	—	—	—	—
Gross Margin %	65.0%	57.4%	51.5%	34.4%	22.9%	1.5%	-45.2%	-34.6%	-148.4%	-28.1%	40.3%	39.9%	36.7%	34.0%	40.2%	—	—	—	—	—	—
Operating Income (EBIT)	$216M	$191M	$139M	$22M	($39M)	($58M)	($65M)	($41M)	($60M)	($39M)	($17M)	($16M)	($16M)	($15M)	($8M)	$0M	$0M	($20M)	($25M)	($30M)	($30M)
Operating Margin %	42.3%	37.5%	32.6%	8.4%	-25.6%	-72.1%	-153.8%	-141.1%	-354.9%	-172.7%	-162.6%	-216.1%	-270.8%	-490.4%	-707.4%	—	—	—	—	—	—
Net Income	$168M	$147M	$198M	($28M)	($66M)	($72M)	($76M)	($48M)	($66M)	($44M)	($20M)	($18M)	($17M)	($16M)	($7M)	$0M	$0M	($20M)	($25M)	($30M)	($30M)
Net Margin %	32.9%	28.8%	46.4%	-10.9%	-42.8%	-88.5%	-179.4%	-164.5%	-387.1%	-192.3%	-183.1%	-250.4%	-284.2%	-506.2%	-653.0%	—	—	—	—	—	—
EBITDA	$234M	$198M	$148M	$5M	($40M)	($53M)	($60M)	($36M)	($57M)	($39M)	($17M)	($16M)	($16M)	($15M)	($8M)	$0M	$0M	($20M)	($25M)	($30M)	—
Earnings Per Share (EPS)	$0.70	$0.60	$0.81	$-0.13	$-0.33	$-0.51	$-0.88	$-0.89	$-1.45	$-1.91	$-1.61	$-1.73	$-1.81	$-2.38	$-1.39	$-0.00	$-0.00	$-0.02	$-0.02	$-0.01	$-11.87
Shares Outstanding (M)	230M	245M	243M	224M	198M	140M	86M	54M	45M	23M	12M	10M	9M	7M	—	1,252M	1,252M	1,252M	1,252M	—	2M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ADMA Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$124M	$114M	$139M	$134M	$122M	$115M	$118M	$120M
Gross Profit	$86M	$81M	$89M	$76M	$67M	$61M	$63M	$60M
Gross Margin %	69.4%	70.5%	63.8%	56.3%	55.1%	53.2%	53.9%	49.8%
Operating Income (EBIT)	$52M	$50M	$63M	$51M	$43M	$35M	$38M	$40M
Operating Margin %	42.2%	43.9%	45.1%	38.0%	35.1%	30.4%	32.6%	33.1%
Net Income	$38M	$45M	$49M	$36M	$34M	$27M	$112M	$36M
Net Margin %	30.4%	39.6%	35.5%	27.1%	28.1%	23.4%	95.2%	30.0%
EBITDA	$57M	$61M	$65M	$51M	$44M	$37M	$40M	$42M
Earnings Per Share (EPS)	$0.16	$0.19	$0.20	$0.15	$0.14	$0.11	$0.46	$0.15
Shares Outstanding (M)	230M	240M	244M	245M	249M	245M	246M	245M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ADMA Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$137M	$50M	$119M	$9M	($60M)	($112M)	($102M)	($76M)	($63M)	($37M)	($18M)	($15M)	($15M)	($11M)	($7M)	$0M	$0M	($24M)	($19M)	($24M)	($24M)
Capital Expenditures (CapEx)	$20M	$23M	$9M	$5M	$14M	$14M	$13M	$4M	$2M	$3M	$0M	$0M	$2M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	$117M	$28M	$110M	$4M	($73M)	($126M)	($115M)	($80M)	($65M)	($40M)	($18M)	($15M)	($17M)	($11M)	($7M)	$0M	$0M	($24M)	($19M)	($24M)	($24M)
FCF Margin %	22.9%	5.5%	25.8%	1.5%	-47.6%	-155.5%	-271.7%	-272.6%	-381.4%	-175.5%	-172.0%	-215.2%	-287.8%	-361.3%	-628.1%	—	—	—	—	—	—
Dividends Paid	—	—	—	—	$3M	$0M	—	—	—	$0M	$0M	$0M	$0M	$0M	$4M	—	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ADMA Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	$30M	$58M	$36M	$13M	$21M	($20M)	$50M	$25M
Capital Expenditures (CapEx)	$2M	$3M	$1M	$14M	$2M	$5M	$3M	$1M
Free Cash Flow (FCF)	$27M	$56M	$35M	($1M)	$19M	($24M)	$47M	$24M
FCF Margin %	21.9%	48.6%	24.8%	-0.8%	15.3%	-21.2%	40.4%	20.0%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ADMA Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$684M	$624M	$489M	$329M	$348M	$276M	$208M	$127M	$89M	$108M	$24M	$24M	$27M	$32M	$16M	$0M	$0M	$9M	$3M	$15M	$15M
Cash & Cash Equivalents	$136M	$88M	$103M	$51M	$87M	$51M	$56M	$27M	$23M	$43M	$10M	$10M	$17M	$26M	$13M	$0M	$0M	$9M	$3M	$15M	$15M
Total Liabilities	$276M	$147M	$140M	$194M	$196M	$135M	$119M	$101M	$69M	$68M	$28M	$23M	$21M	$10M	$6M	$0M	$0M	$9M	$3M	$15M	$15M
Total Debt (Short + Long-Term)	$198M	$73M	$74M	$132M	$144M	$95M	$93M	$69M	$29M	$31M	$18M	$14M	$15M	$5M	$4M	$0M	$0M	$0M	$0M	$0M	$0M
Total Shareholders' Equity	$408M	$477M	$349M	$135M	$152M	$141M	$88M	$26M	$20M	$40M	($4M)	$1M	$6M	$22M	$9M	$0M	$0M	($3M)	($13M)	$5M	$0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ADMA viewer.

Other Companies in BIOTECHNOLOGY

NUVB · Nuvation Bio Inc — $2 billion
RXRX · Recursion Pharmaceuticals Inc — $2 billion
ZBIO · Zenas BioPharma, Inc. Common Stock — $2 billion
VCEL · Vericel Corp Ord — $2 billion
AGIO · Agios Pharm — $2 billion
MESO · Mesoblast Ltd — $2 billion
RAPP · Rapport Therapeutics, Inc. Common Stock — $2 billion
GHRS · GH Research PLC — $2 billion

← ADM All “A” companies ADME →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.